One-year outcome following biological or mechanical valve replacement for infective endocarditis
F Delahaye, VH Chu, J Altclas, B Barsic, A Delahaye, T Freiberger, DL Gordon, MM Hannan, B Hoen, SS Kanj, T Lejko-Zupanc, CA Mestres, O Pachirat, P Pappas, C Lamas, C Selton-Suty, R Tan, P Tattevin, A Wang
INTERNATIONAL JOURNAL OF CARDIOLOGY | ELSEVIER IRELAND LTD | Published : 2015
BACKGROUND: Nearly half of patients require cardiac surgery during the acute phase of infective endocarditis (IE). We describe the characteristics of patients according to the type of valve replacement (mechanical or biological), and examine whether the type of prosthesis was associated with in-hospital and 1-year mortality. METHODS AND RESULTS: Among 5591 patients included in the International Collaboration on Endocarditis Prospective Cohort Study, 1467 patients with definite IE were operated on during the active phase and had a biological (37%) or mechanical (63%) valve replacement. Patients who received bioprostheses were older (62 vs 54years), more often had a history of cancer (9% vs 6%..View full abstract
Awarded by AHA Mid-Atlantic
Dr. Wang is supported in part by AHA Mid-Atlantic Grant-in-Aid Award #12GRNT12030071.r Dr Kanj declared honoraria for talks from Pfizer, Merck, Astra Zeneca, Astellas, Biologix and research funds from Astellas.